+61 2 9452 6666 how to order

Australian Biotechnologies is an innovative and progressive company focusing on improving the quality of Allograft products available to the Australian market.

Allovance® Crunch is an advanced CO2 treated, 100% natural, Australian made Allograft used diversely in both Orthopaedic and Spinal surgery.

Over 8000 Australian cases to date our Allovance® Crunch has a clinically proven track record backed by Australian Research.

Please contact us if you require copies of our studies, white papers and case studies

Allograft Bone & Allovance® Crunch

Allograft tissues provide surgeons with a reliable and convenient source of human tissue for use in reconstructive surgery of bone defects. The goal of using bone allografts is to initiate a biological healing response from the host bone bed and promote new bone formation at the surgical site.

Biomechanical testing of allograft and CO2 treatment

Rigorous allograft bone processing is required prior to use in order to minimize the possibility of an immune response or disease transmission. While effective at removing these infectious agents, these treatments have also been associated with deleterious effects on the mechanical properties of the graft.

Effects of 25kGy Gamma Irradiation and CO2 treatment on the Permeability of Bovine Cortical Bone

The flow of interstitial fluid (ISF) and blood through bone is considered an imperative mechanism affecting bone remodelling and fracture healing. ISF and blood flow enhances the transport of nutrients to cells and provides a means for waste removal.

Allovance Technical Monograph

Degenerative conditions of the lumbar and cervical spine are a leading cause of disability and consequently a major social expense. Treatment of these conditions, spinal fusion, usually involves fusion of adjacent vertebrae into a solid bone mass in order to minimize motion between the vertebrae.

The Osteoconductivity of Allovance® Crunch in a Critical-Sized Defect Model in Rabbits

Clinically, allogeneic bone is used extensively because it avoids the donor site morbidity associated with autograft. However, there are concerns over the optimal processing techniques to eliminate immunological risks whilst maintaining the biological efficacy of the graft.